Literature DB >> 11297964

Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients.

T Menges, P W Hermans, S G Little, T Langefeld, O Böning, J Engel, M Sluijter, R de Groot, G Hempelmann.   

Abstract

A single base pair insertion/deletion (4G/SG) promoter polymorphism in the plasminogen-activator-inhibitor-1 (PAI-1) gene is thought to play a part in prognosis after severe trauma. We investigated the relation between outcome of severe trauma, PAI-1 concentrations, and PAP-1 genotype in 61 patients who had been severely injured. 11 (58%) of 19 patients with genotype 4G/4G did not survive, whereas only eight (28%) of 29 patients with heterozygous genotype 4G/SG, and two (15%) of 13 patients with genotype 5G/5G died. The PAI-1 4G allele is associated with high concentrations of PAI-1 in plasma and a poor survival rate after severe trauma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297964     DOI: 10.1016/S0140-6736(00)04311-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

1.  4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.

Authors:  Francesco Burzotta; Licia Iacoviello; Augusto Di Castelnuovo; Roberto Zamparelli; Andria D'Orazio; Concetta Amore; Rocco Schiavello; Maria Benedetta Donati; Attilio Maseri; GianFederico Possati; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery.

Authors:  Gonzalo Sirgo; José Luis Pérez-Vela; Pablo Morales; Manuel Del Rey; Joan Vendrell; Cristina Gutierrez; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-03-01       Impact factor: 17.440

3.  Ethical considerations in the collection of genetic data from critically ill patients: what do published studies reveal about potential directions for empirical ethics research?

Authors:  B D Freeman; C R Kennedy; H L Frankel; B Clarridge; D Bolcic-Jankovic; E Iverson; E Shehane; A Celious; B A Zehnbauer; T G Buchman
Journal:  Pharmacogenomics J       Date:  2009-12-08       Impact factor: 3.550

Review 4.  Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome.

Authors:  Sara C Sebag; Julie A Bastarache; Lorraine B Ware
Journal:  Curr Pharm Biotechnol       Date:  2011-09       Impact factor: 2.837

Review 5.  Genetic determinants and ethnic disparities in sepsis-associated acute lung injury.

Authors:  Kathleen C Barnes
Journal:  Proc Am Thorac Soc       Date:  2005

6.  An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients.

Authors:  Catherine F Li; Robert Y Wei; Frank Baliko; Bharati Bapat; Benjamin A Alman
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

7.  A mathematical model of pulmonary gas exchange under inflammatory stress.

Authors:  Angela Reynolds; G Bard Ermentrout; Gilles Clermont
Journal:  J Theor Biol       Date:  2010-01-18       Impact factor: 2.691

8.  4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study.

Authors:  Krisztina Madách; István Aladzsity; Agnes Szilágyi; George Fust; János Gál; István Pénzes; Zoltán Prohászka
Journal:  Crit Care       Date:  2010-04-29       Impact factor: 9.097

9.  Mitogen-activated protein kinases in the intensive care unit: prognostic potential.

Authors:  Matthew R Rosengart; Avery B Nathens; Saman Arbabi; Margaret J Neff; Iris Garcia; Thomas R Martin; Ronald V Maier
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

10.  A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia.

Authors:  Kevin K Kim; Kevin R Flaherty; Qi Long; Noboru Hattori; Thomas H Sisson; Thomas V Colby; William D Travis; Fernando J Martinez; Susan Murray; Richard H Simon
Journal:  Mol Med       Date:  2003 Jan-Feb       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.